Abiopharma

🔍 Thurman Alex R. (Executive)

Company: GLAUKOS Corp (GKOS)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Sold 1,230 shares of Common Stock at $106.84 per share (Direct)
  Date: 2026-03-23 | Code: F | equity_swap_involved: 0 | shares_owned_after: 48,019.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,521 shares of Common Stock at $105.24 per share (Direct)
  Date: 2026-03-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 46,498.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 2,020 shares of Common Stock at $105.23 per share (Direct)
  Date: 2026-03-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 44,478.00 | transaction_form_type: 4 | Footnotes: F4, F5

Footnotes:

• F1: Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock underlying restricted stock units previously granted by the Issuer on March 22, 2023.
• F2: Includes 9,761 restricted stock units that have not yet vested or been delivered to the Reporting Person.
• F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
• F4: Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock underlying restricted stock units previously granted by the Issuer on March 24, 2022.
• F5: Includes 5,230 restricted stock units that have not yet vested or been delivered to the Reporting Person.